Cystic fibrosis drug set for rejection
A €220,000 `wonder drug' to treat cystic fibrosis is set to be rejected for use in the Irish health service.
A €220,000 "wonder drug" to treat cystic fibrosis (CF) is set to be rejected for use in the Irish health service after the manufacturer was told there were serious obstacles to the Irish taxpayer covering the cost.
Kalydeco, which is manufactured by Vertex Pharmaceuticals, is the first and only drug that treats the underlying cause of CF rather than the symptoms of the condition.
It is too early to say whether Kalydeco will be a...
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
*New subscribers only
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Unlimited Access for 2 Years
Get a Business Account for you and your team